BigHat Biosciences, a biotechnology company, has entered a strategic collaboration with Eli Lilly and Company.

Eli Lilly announced plans to manufacture its new weight loss pill, orforglipron, in the U.S., with global distribution set to begin in 2026, Bloomberg reported April 18. The move comes as President ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

The Global Active Pharmaceutical Ingredients Market achieved a valuation of $209.80 Billion in 2024 and is anticipated to exceed $445.7 Billion by 2035, reflecting a compounded annual growth rate ...

Eli Lilly & Co.’s shares fell Monday morning after the Trump administration spiked a plan late last week to pay for obesity drugs for Medicare patients. The Centers for Medicare and Medicaid ...

The active pharmaceutical ingredient (API) in Mounjaro, the weight-loss drug produced by Eli Lilly, is Ireland’s biggest pharmaceutical export to the US, and would be the hardest hit if US ...